Modality
Fusion Protein
MOA
USP1i
Target
HER2
Pathway
Tau
CeliacCrohn's
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
~Dec 2021
→ ~Mar 2023
Phase 3
Jun 2023
→ Oct 2029
Phase 3Current
NCT06501643
2,672 pts·Crohn's
2023-06→2029-10·Active
2,672 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-043.5y awayPh3 Readout· Crohn's
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Active
Catalysts
Ph3 Readout
2029-10-04 · 3.5y away
Crohn's
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06501643 | Phase 3 | Crohn's | Active | 2672 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| ITO-535 | iTeos | NDA/BLA | MDM2 | |
| Tezeratamab | Prime Medicine | Phase 3 | CGRP |